April 2016

New Product - Genvoya

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is a fixed dose combination of elvitegravir (integrase strand transfer inhibitor), boosted by cobicistat (pharmacokinetic enhancer), emtricitabine and tenofovir alafenamide (NRTIs). Genvoya is indicated for the treatment of HIV-1 infection in adults and adolescents aged 12 years of age and older with a bodyweight of at least 35 kg who are either treatment naïve; or virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen. Patients must not have a history of treatment failure or known mutations associated with resistance to the antiretroviral components of Genvoya. Genvoya is contraindicated with the following medicines: alfuzosin, carbamazepine, phenobarbitone, phenytoin, rifampicin, dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride, St John’s wort, lovastatin, simvastatin, pimozide, orally administered midazolam or triazolam, and sildenafil for the treatment of pulmonary arterial hypertension. Genvoya is available as a single tablet regimen (containing 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and tenofovir alafenamide fumarate (equivalent to 10 mg of tenofovir alafenamide)) in packs of 30’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629